David L. Kemmerly Sells 3,375 Shares of Amedisys Inc (AMED) Stock

Amedisys Inc (NASDAQ:AMED) insider David L. Kemmerly sold 3,375 shares of the stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $117.44, for a total transaction of $396,360.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

David L. Kemmerly also recently made the following trade(s):

  • On Friday, November 9th, David L. Kemmerly sold 6,500 shares of Amedisys stock. The stock was sold at an average price of $118.87, for a total transaction of $772,655.00.

Amedisys stock traded up $1.46 during mid-day trading on Friday, reaching $120.50. The company’s stock had a trading volume of 476,700 shares, compared to its average volume of 343,222. The company has a market cap of $3.57 billion, a P/E ratio of 54.52, a price-to-earnings-growth ratio of 1.67 and a beta of 1.22. Amedisys Inc has a 12 month low of $49.80 and a 12 month high of $127.38. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.12.

Amedisys (NASDAQ:AMED) last released its earnings results on Monday, October 29th. The health services provider reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.18. The business had revenue of $417.34 million during the quarter, compared to the consensus estimate of $411.05 million. Amedisys had a net margin of 5.39% and a return on equity of 23.27%. The firm’s revenue for the quarter was up 11.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.56 earnings per share. On average, equities research analysts forecast that Amedisys Inc will post 3.58 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the stock. Itau Unibanco Holding S.A. bought a new position in Amedisys in the second quarter valued at $149,000. Moneta Group Investment Advisors LLC bought a new position in shares of Amedisys in the 2nd quarter valued at about $181,000. Cubist Systematic Strategies LLC grew its position in shares of Amedisys by 1,086.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 2,372 shares of the health services provider’s stock valued at $203,000 after acquiring an additional 2,172 shares during the period. Dorsey & Whitney Trust CO LLC bought a new position in shares of Amedisys in the 3rd quarter valued at about $203,000. Finally, Quantitative Systematic Strategies LLC bought a new position in shares of Amedisys in the 2nd quarter valued at about $217,000. 93.58% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts have recently issued reports on the stock. Craig Hallum downgraded shares of Amedisys from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $116.00 to $104.00 in a research report on Friday, October 26th. Bank of America set a $139.00 price objective on shares of Amedisys and gave the stock a “buy” rating in a research report on Tuesday, September 18th. ValuEngine raised shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 30th. BidaskClub raised shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Finally, Canaccord Genuity assumed coverage on shares of Amedisys in a research report on Thursday, September 13th. They set a “neutral” rating and a $117.00 price objective for the company. Five investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $105.50.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/11/09/david-l-kemmerly-sells-3375-shares-of-amedisys-inc-amed-stock.html.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Featured Article: How to Invest in a Bull Market

Insider Buying and Selling by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply